Glossip v. Gross
Headline: Court affirms Oklahoma’s use of midazolam in its three‑drug lethal injection protocol, allowing executions to proceed because inmates failed to show a known, available safer alternative or clear pain risk.
Holding: The Court affirmed the denial of a preliminary injunction, ruling that the inmates failed to identify a known and available less‑painful execution method and that the District Court’s finding that 500 mg midazolam prevents severe pain was not clearly erroneous.
- Allows Oklahoma to continue using its midazolam three‑drug execution protocol.
- Requires inmates to identify a known, available less‑painful alternative method.
- Gives courts deference to trial findings about drug effectiveness in execution cases.
Summary
Background
Four men on Oklahoma’s death row challenged the State’s switched execution method after Oklahoma replaced pentobarbital with midazolam in a three‑drug lethal injection protocol. The inmates sought a preliminary injunction after an evidentiary hearing in which experts debated whether midazolam can keep a person insensate to the paralytic and potassium chloride that follow. Oklahoma had previously used midazolam in executions that raised problems, notably the Lockett execution where IV access failed, and it revised its protocol to require a 500 mg dose of midazolam plus procedural safeguards.
Reasoning
The Court had to decide whether the State’s planned use of midazolam creates an unacceptable risk of severe pain and whether the inmates identified an available, less‑risky alternative. Applying the standard from Baze v. Rees, the Court affirmed for two independent reasons. First, the inmates did not identify any known and available alternative drug because the District Court found sodium thiopental and pentobarbital unavailable. Second, the District Court’s factual finding that a 500 mg dose of midazolam is highly likely to render a person insensate was not clearly erroneous under the deferential review standard, and the record included expert testimony supporting that finding.
Real world impact
The ruling lets Oklahoma continue using its revised midazolam‑first protocol and makes it harder to obtain a court stay based on midazolam alone unless a prisoner shows a known, available safer option or clear proof of a severe risk. The decision emphasizes deference to trial‑court factfinding in scientific disputes about execution drugs.
Dissents or concurrances
Several Justices wrote separately. Two Justices concurred. Justice BREYER (joined by Justice GINSBURG) urged full briefing on whether the death penalty itself is constitutional, citing reliability, arbitrariness, and delay concerns. Justice SOTOMAYOR (with Justice GINSBURG and others) dissented on the midazolam facts and criticized the Court’s new emphasis on identifying alternatives.
Ask about this case
Ask questions about the entire case, including all opinions (majority, concurrences, dissents).
What was the Court's main decision and reasoning?
How did the dissenting opinions differ from the majority?
What are the practical implications of this ruling?